Premium
NF‐κB activator Act1 associates with IL‐1/Toll pathway adaptor molecule TRAF6
Author(s) -
Kanamori Mutsumi,
Kai Chikatoshi,
Hayashizaki Yoshihide,
Suzuki Harukazu
Publication year - 2002
Publication title -
febs letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.593
H-Index - 257
eISSN - 1873-3468
pISSN - 0014-5793
DOI - 10.1016/s0014-5793(02)03688-8
Subject(s) - signal transducing adaptor protein , activator (genetics) , nf κb , microbiology and biotechnology , chemistry , tlr4 , signal transduction , p50 , nfkb1 , tumor necrosis factor alpha , receptor , mutant , toll like receptor , transcription factor , biology , biochemistry , innate immune system , gene , immunology
NF‐κB activator 1 (Act1), also called CIKS, is a recently identified protein with NF‐κB and AP‐1 activation activities through its association with the IκB kinase complex. We identified and confirmed that Act1 interacts with tumor necrosis factor receptor‐associated factor 6 (TRAF6); notably, Act1 binds to TRAF6 only among TRAF family proteins. The amino‐terminal half of Act1 is required for its interaction with the TRAF domain. Act1‐mediated NF‐κB activation was inhibited by a dominant‐negative mutant of TRAF6 in a dose‐dependent manner, and IL‐1‐induced NF‐κB activation was inhibited by a high level of Act1 expression. Our results suggest that Act1 is involved in IL‐1/Toll‐mediated signaling through TRAF6.